These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 29885478)

  • 1. Prolonged Leptomeningeal Responses with Brigatinib in Two Heavily Pretreated ALK-Rearranged Non-Small Cell Lung Cancer Patients.
    Geraud A; Mezquita L; Bigot F; Caramella C; Planchard D; Le Pechoux C; Besse B
    J Thorac Oncol; 2018 Nov; 13(11):e215-e217. PubMed ID: 29885478
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
    Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
    Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brigatinib-induced tuberculosis reactivation: A case report.
    Keş V; Sütcüoğlu O; Gürler F; Yazıcı O; Özet A
    Curr Probl Cancer; 2021 Dec; 45(6):100738. PubMed ID: 33867154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brigatinib effective in ALK-positive non-small-cell lung cancer.
    Das M
    Lancet Oncol; 2017 Jun; 18(6):e310. PubMed ID: 28506557
    [No Abstract]   [Full Text] [Related]  

  • 5. Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.
    Kim DW; Tiseo M; Ahn MJ; Reckamp KL; Hansen KH; Kim SW; Huber RM; West HL; Groen HJM; Hochmair MJ; Leighl NB; Gettinger SN; Langer CJ; Paz-Ares Rodríguez LG; Smit EF; Kim ES; Reichmann W; Haluska FG; Kerstein D; Camidge DR
    J Clin Oncol; 2017 Aug; 35(22):2490-2498. PubMed ID: 28475456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brigatinib for
    Ali R; Arshad J; Palacio S; Mudad R
    Drug Des Devel Ther; 2019; 13():569-580. PubMed ID: 30804663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brigatinib: First Global Approval.
    Markham A
    Drugs; 2017 Jul; 77(10):1131-1135. PubMed ID: 28597393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brigatinib versus crizotinib for ALK-positive NSCLC.
    Stirrups R
    Lancet Oncol; 2018 Nov; 19(11):e585. PubMed ID: 30293790
    [No Abstract]   [Full Text] [Related]  

  • 9. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.
    Sehgal K; Peters MLB; VanderLaan PA; Rangachari D; Kobayashi SS; Costa DB
    J Thorac Oncol; 2019 Jan; 14(1):e1-e3. PubMed ID: 29981924
    [No Abstract]   [Full Text] [Related]  

  • 10. Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
    Gaye E; Geier M; Bore P; Guilloïque M; Lucia F; Quéré G; Gouva S; Robinet G; Descourt R
    Lung Cancer; 2019 Jul; 133():1-3. PubMed ID: 31200813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported outcomes and quality of life in advanced ALK+ non-small-cell lung cancer trial of brigatinib (ALTA).
    Lenderking WR; Lin H; Speck RM; Zhu Y; Huang H; Huang J; Kerstein D; Langer CJ
    Future Oncol; 2019 Aug; 15(24):2841-2855. PubMed ID: 31364872
    [No Abstract]   [Full Text] [Related]  

  • 12. Brigatinib for the treatment of ALK-positive advanced non-small cell lung cancer patients.
    Passaro A; Prelaj A; Pochesci A; Spitaleri G; Rossi G; Del Signore E; Catania C; de Marinis F
    Drugs Today (Barc); 2017 Aug; 53(8):435-446. PubMed ID: 29119148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploratory Analysis of Brigatinib Activity in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer and Brain Metastases in Two Clinical Trials.
    Camidge DR; Kim DW; Tiseo M; Langer CJ; Ahn MJ; Shaw AT; Huber RM; Hochmair MJ; Lee DH; Bazhenova LA; Gold KA; Ou SI; West HL; Reichmann W; Haney J; Clackson T; Kerstein D; Gettinger SN
    J Clin Oncol; 2018 Sep; 36(26):2693-2701. PubMed ID: 29768119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Converting EORTC QLQ-C30 scores to utility scores in the brigatinib ALTA study.
    Kawata AK; Lenderking WR; Eseyin OR; Kerstein D; Huang J; Huang H; Zhang P; Lin HM
    J Med Econ; 2019 Sep; 22(9):924-935. PubMed ID: 31125274
    [No Abstract]   [Full Text] [Related]  

  • 15. The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer.
    Amanam I; Gupta R; Mambetsariev I; Salgia R
    Future Oncol; 2018 Aug; 14(19):1897-1908. PubMed ID: 29451020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second- and third-generation ALK inhibitors for non-small cell lung cancer.
    Wu J; Savooji J; Liu D
    J Hematol Oncol; 2016 Mar; 9():19. PubMed ID: 26951079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brigatinib (Alunbrig) for non-small cell lung cancer.
    Med Lett Drugs Ther; 2018 Apr; 60(1545):e72-e73. PubMed ID: 29667950
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal management of ALK-positive NSCLC progressing on crizotinib.
    Metro G; Tazza M; Matocci R; Chiari R; Crinò L
    Lung Cancer; 2017 Apr; 106():58-66. PubMed ID: 28285695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brigatinib Effective in ALK+ NSCLC.
    Cancer Discov; 2017 Jan; 7(1):4-5. PubMed ID: 27899405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early Onset Pulmonary Toxicity With Lorlatinib in a Patient With Previous Pulmonary Toxicity From Brigatinib.
    Monzonís X; Arriola E
    J Thorac Oncol; 2019 Nov; 14(11):e247-e248. PubMed ID: 31668321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.